Metabolic Regulation of Glioma Stem-like Cells in the Tumor Micro-environment

Overview

Journal Cancer Lett

Specialty Oncology

Date 2017 Jul 27

PMID 28743531

Citations 20

Authors

Tom M Thomas

John S Yu

Affiliations

Soon will be listed here.

Abstract

Cancer metabolism has emerged as one of the most interesting old ideas being revisited from a new perspective. In the early 20th century Otto Warburg declared metabolism the prime cause in a disease of many secondary causes, and this statement seems more prescient in view of modern expositions into the true nature of tumor evolution. As the complexity of tumor heterogeneity becomes more clear from a genetic perspective, it is important to consider the inevitably heterogeneous metabolic components of the tumor and the tumor microenvironment. High grade gliomas remain one of the most difficult to treat solid tumors, due in part to the highly vascularized nature of the tumor and the maintenance of more resistant stem-like subpopulations within the tumor. Maintenance of glioma stem cells (GSCs) requires specific alterations within the cells and the greater tumor microenvironment with regards to signaling and metabolism. Specific niches within gliomas help foster the survival of stem-like sub-populations of cells with high tumorigenicity and high metabolic plasticity. Understanding these maintenance pathways and the metabolic dependencies within the niche may highlight potential avenues of addressing tumor resistance and recurrence in glioma patients.

Citing Articles

Construction of a Prognostic Model for Mitochondria and Macrophage Polarization Correlation in Glioma Based on Single-Cell and Transcriptome Sequencing.

Chen P, Wang H, Zhang Y, Qu S, Zhang Y, Yang Y CNS Neurosci Ther. 2024; 30(11):e70083.

PMID: 39491527 PMC: 11532235. DOI: 10.1111/cns.70083.

Targeting Wnt signaling for improved glioma immunotherapy.

Gutova M, Hibbard J, Ma E, Natri H, Adhikarla V, Chimge N Front Immunol. 2024; 15:1342625.

PMID: 38449858 PMC: 10915090. DOI: 10.3389/fimmu.2024.1342625.

Heterogeneity in clinical prognosis, immune infiltration and molecular characteristics of three glycolytic subtypes in lower-grade gliomas.

Wu S, Sheng L, Fan S, Guo X, Zhu B, Wu C Front Oncol. 2023; 13:1180662.

PMID: 37274274 PMC: 10233122. DOI: 10.3389/fonc.2023.1180662.

Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy.

Hersh A, Gaitsch H, Alomari S, Lubelski D, Tyler B Cancers (Basel). 2022; 14(15).

PMID: 35954407 PMC: 9367289. DOI: 10.3390/cancers14153743.

Extracellular vesicles derived from glioblastoma promote proliferation and migration of neural progenitor cells via PI3K-Akt pathway.

Pan J, Sheng S, Ye L, Xu X, Ma Y, Feng X Cell Commun Signal. 2022; 20(1):7.

PMID: 35022057 PMC: 8756733. DOI: 10.1186/s12964-021-00760-9.

References

Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J . Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res. 2010; 70(5):2030-40. DOI: 10.1158/0008-5472.CAN-09-1707. View

Pattabiraman D, Weinberg R . Tackling the cancer stem cells - what challenges do they pose?. Nat Rev Drug Discov. 2014; 13(7):497-512. PMC: 4234172. DOI: 10.1038/nrd4253. View

Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

Rohwer N, Cramer T . Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011; 14(3):191-201. DOI: 10.1016/j.drup.2011.03.001. View

Chandran U, Luthra S, Santana-Santos L, Mao P, Kim S, Minata M . Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells. Genom Data. 2015; 5:333-336. PMC: 4523279. DOI: 10.1016/j.gdata.2015.07.007. View

Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

Brat D, Castellano-Sanchez A, Hunter S, Pecot M, Cohen C, Hammond E . Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004; 64(3):920-7. DOI: 10.1158/0008-5472.can-03-2073. View

Lamb R, Bonuccelli G, Ozsvari B, Peiris-Pages M, Fiorillo M, Smith D . Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. Oncotarget. 2015; 6(31):30453-71. PMC: 4741544. DOI: 10.18632/oncotarget.5852. View

Endaya B, Lam P, Meedeniya A, Neuzil J . Transcriptional profiling of dividing tumor cells detects intratumor heterogeneity linked to cell proliferation in a brain tumor model. Mol Oncol. 2015; 10(1):126-37. PMC: 5528932. DOI: 10.1016/j.molonc.2015.09.001. View

10.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

11.

Schonberg D, Lubelski D, Miller T, Rich J . Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med. 2013; 39:82-101. PMC: 3866208. DOI: 10.1016/j.mam.2013.06.004. View

12.

McCord A, Jamal M, Shankavaram U, Shankavarum U, Lang F, Camphausen K . Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res. 2009; 7(4):489-97. PMC: 6290460. DOI: 10.1158/1541-7786.MCR-08-0360. View

13.

Dong C, Yuan T, Wu Y, Wang Y, Fan T, Miriyala S . Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013; 23(3):316-31. PMC: 3703516. DOI: 10.1016/j.ccr.2013.01.022. View

14.

Saga I, Shibao S, Okubo J, Osuka S, Kobayashi Y, Yamada S . Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model. Neuro Oncol. 2014; 16(8):1048-56. PMC: 4096179. DOI: 10.1093/neuonc/nou096. View

15.

Keibler M, Wasylenko T, Kelleher J, Iliopoulos O, Vander Heiden M, Stephanopoulos G . Metabolic requirements for cancer cell proliferation. Cancer Metab. 2016; 4:16. PMC: 4989334. DOI: 10.1186/s40170-016-0156-6. View

16.

De Luca A, Fiorillo M, Peiris-Pages M, Ozsvari B, Smith D, Sanchez-Alvarez R . Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget. 2015; 6(17):14777-95. PMC: 4558115. DOI: 10.18632/oncotarget.4401. View

17.

Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S . Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009; 15(6):501-13. PMC: 2693960. DOI: 10.1016/j.ccr.2009.03.018. View

18.

Clement V, Sanchez P, De Tribolet N, Radovanovic I, Ruiz i Altaba A . HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007; 17(2):165-72. PMC: 1855204. DOI: 10.1016/j.cub.2006.11.033. View

19.

Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R . TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene. 2009; 28(18):1960-70. DOI: 10.1038/onc.2009.61. View

20.

Fidoamore A, Cristiano L, Antonosante A, dAngelo M, Di Giacomo E, Astarita C . Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. Stem Cells Int. 2016; 2016:6809105. PMC: 4736577. DOI: 10.1155/2016/6809105. View